Newron to Present at the 16th International Congress on Schizophrenia Research

Phase 2 study evaluated safety, tolerability, and preliminary evidence of efficacy of Evenamide (NW-3509) as an add-on to antipsychotics in patients with schizophrenia

Milan, Italy - March 16, 2017 - Newron Pharmaceuticals S.p.A. ("Newron"), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, today announces that Ravi Anand, M.D., Newron's Chief Medical Officer, will make an oral presentation entitled "Evenamide, a Putative Antipsychotic, Targets Abnormal Electrical Activity and Glutamatergic Abnormalities to Improve Psychotic Symptoms in Patients With Schizophrenia: Results From a Phase II, Placebo-Controlled Trial" at the 16th International Congress on Schizophrenia Research, ICOSR, taking place on March 24-28, 2017 at the Manchester Grand Hyatt in San Diego, California, USA.

The abstract will be presented on Saturday, March 25, 3:45-4:00 pm PT, as part of the "Clinical Trials" oral session in Seaport Ballroom F.

Evenamide (NW-3509) is a new generation antipsychotic that acts through pathways not targeted by current treatments or other putative antipsychotics. It is associated with a functional blockade of voltage-gated sodium channels that inhibits glutamate release by reducing the firing rate of hyper-excited neurons and may normalize aberrant cortical and hippocampal activity.

The double-blind, 28-day, placebo-controlled, Phase 2 study evaluated safety, tolerability, and preliminary evidence of efficacy of Evenamide as an add-on to a stable dose of risperidone or aripiprazole in 89 schizophrenia outpatients. Patients received placebo or Evenamide (15-25mg bid). The dose escalation from 15 to 20 to 25 mg bid was done weekly in an inpatient setting, based on tolerability. The study concludes that the combination of Evenamide as an add-on to marketed antipsychotics in patients showing return of symptoms would combine reduction of aberrant electrical activity and normalization of glutamate release with blockade of 5HT2/D2 receptors, thus producing a novel therapeutic option.

About Newron Pharmaceuticals

Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy, with a subsidiary in Morristown, NJ, USA. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson's disease in the European Union and Switzerland and is commercialized by Newron's partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson's disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for

patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. www.newron.com.

For more information

Media	**Investors and Analysts**
Newron Stefan Weber – CEO Phone: +39 02 6103 46 26 E-mail: pr@newron.com **UK/Europe** Julia Phillips FTI Consulting Phone: +44 (0)20 3727 1000 **Switzerland** Martin Meier-Pfister IRF Communications Phone: +41 43 244 81 40 **Germany** Anne Hennecke MC Services AG Phone: +49 211 52925222 **USA** Beth Kurth LaVoieHealthScience Phone: +1 617 374 8800, Ext. 106	**Newron** Stefan Weber – CEO Phone: +39 02 6103 46 26 E-mail: ir@newron.com **UK/Europe** Julia Phillips FTI Consulting Phone: +44 (0)20 3727 1000 **Germany** Anne Hennecke MC Services AG Phone: +49 211 52925222 **USA** Beth Kurth LaVoieHealthScience Phone: +1 617 374 8800, Ext. 106

Important Notices

This document contains forward-looking statements, including (without limitation) about (1) Newron' s ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialisation of its product candidates and reduce costs (including staff costs), (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron's anticipated future revenues, capital expenditures and financial resources, and (4) assumptions underlying any such statements. In some cases these statements and assumptions can be identified by the fact that they use words such as " will", anticipate", " estimate", " expect", " project", "intend", " plan", "believe", " target", and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements.

By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions.

Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programmes, development activities, commercialisation plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions.

Newron does not undertake any obligation to publicly up-date or revise forward looking statements except as may be required by applicable regulations of the SIX Swiss Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.